Clinical trials
Melanoma (Skin Cancer) clinical trials
Below are recruiting melanoma (skin cancer) clinical trials, each written for real people, not researchers. We’re tracking 153 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07760012Recruiting
Pet scan with new tracer for solid tumors
This study uses a new imaging tracer, called 68Ga-SorB, during a PET/CT scan to look at tumors. It may help doctors see cancer more clearly. The trial is for adults with certain types of solid tumors (such as melanoma, liver, lung, breast, pancreatic, ovarian, or bile duct cancer) who need a PET/CT scan as part of their care.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05620290RecruitingPhase 1
MR-guided ultrasound plus radiation to help skin cancer respond
This Phase 1 study tests a new way to make radiation work better using MRI-guided focused ultrasound. It focuses on improving treatment for malignant melanoma and other skin cancers, while checking safety and how patients experience treatment.
Toronto, OntarioAges 18 years+ - NCT07848243RecruitingPhase 2
A new imaging test to find returning cancer
This trial tests a new imaging agent that helps find cancer cells that have come back. It is given as an injection and then a scan is done to see if it helps doctors locate the cancer.
BeijingAges 18 years+ - NCT07830225Recruiting
Using a blood test to guide how long immunotherapy continues for advanced melanoma
This study looks at using a blood test that detects tiny pieces of cancer DNA (called ctDNA) to help decide how long patients with advanced melanoma should stay on immunotherapy. It may help some patients safely stop treatment earlier if the blood test shows the cancer is under control.
New Brunswick, New JerseyAges 18–90 - NCT07808164Recruiting
Protein markers in solid tumors: a Vietnamese tissue study
This study looks at tissue samples from Vietnamese patients with solid tumors to understand the presence of certain proteins (ENPP1, cGAS, and FAP). The goal is to learn more about these tumors, which might help develop better treatments in the future.
Hanoi, HanoiAges 18 years+ - NCT04498767Recruiting
Radiation to treat a few metastatic spots in rare cancers
This trial studies whether stereotactic (high-precision) radiation given in a few sessions can control rare cancers that have spread to a small number of sites. It aims to help by treating all known spots while keeping side effects manageable.
AnderlechtAges 18 years+ - NCT07740941RecruitingPhase 2
Neoadjuvant, spare-adjuvant (NASA) in stage IIIB-IV (M1a) melanoma
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
Chapel Hill, North CarolinaAges 18 years+ - NCT06621810Recruiting
AI for melanoma detection in children and young adults
This study uses artificial intelligence to help detect melanoma (a type of skin cancer) and predict risk in children, teens, and young adults. Researchers want to see if AI can spot melanoma early and assess risk better.
TübingenAges Any age - NCT07718243RecruitingPhase 1/Phase 2
Combining two immunotherapies for solid tumors, melanoma, and lung cancer
This trial tests a new drug (bexmarilimab) plus nivolumab (an approved immunotherapy) for people with advanced solid tumors, melanoma, or non-small cell lung cancer (NSCLC) that has stopped responding to standard treatments.
ManchesterAges 18 years+ - NCT07686835RecruitingPhase 2
High-fiber diet to help immunotherapy work better in advanced melanoma
This trial tests if adding extra dietary fiber before and during immunotherapy can change gut bacteria to make the treatment more effective. It is for people with advanced melanoma who are about to start their first immunotherapy.
Nijmegen, GelderlandAges 18 years+ - NCT07661966Recruiting
Bright light therapy for melanoma or lung cancer patients starting immunotherapy
This study tests if daily bright light therapy can help people with advanced melanoma or lung cancer feel better during their first immunotherapy treatment. The light box is used at home for a short time each morning.
New York, New YorkAges 18 years+ - NCT07649681Recruiting
AI nutrition help for taste changes from cancer treatment
This study tests whether an AI-powered nutrition program can help people with taste changes caused by cancer therapy. You'll get personalized recipe suggestions and nutrition advice through an online portal to help you eat better during treatment.
Augsburg, BavariaAges 18 years+ - NCT07586904RecruitingEarly Phase 1
New Immunotherapy Combination for Advanced Melanoma
This trial tests a combination of two drugs (cadonilimab and interferon) given before surgery to treat advanced melanoma that has spread to nearby lymph nodes or one distant site. The goal is to shrink tumors and improve chances of successful surgery and long-term survival.
Xi'anAges 18–75 - NCT07586891Recruiting
Low-Branched-Chain Amino Acid Diet With Immunotherapy for Stage III Melanoma
This trial tests whether a special diet low in certain amino acids (building blocks of protein), combined with an immune-boosting antibody drug, can safely shrink stage III melanoma that has spread to lymph nodes. The goal is to see if this combination works better than standard treatment.
Xi'anAges 18–75 - NCT07584291Recruiting
Blood Tests and Tissue Study for Melanoma
This research study analyzes blood and tissue samples from melanoma patients to identify biological markers that could help doctors better understand and treat the disease. Researchers will examine archived tissue samples and blood work to develop improved diagnostic tools.
Xi'an, ShaanxiAges 18–80 - NCT07555210Recruiting
Bone Density Changes During Cancer Immunotherapy
This study tracks how a type of cancer treatment called anti-PD-1 immunotherapy affects bone strength over time. Researchers want to understand whether this treatment causes bone density loss and help develop ways to protect bones during cancer care.
Nashville, TennesseeAges 18 years+ - NCT07556380Recruiting
Mobile app to help melanoma survivors stay safe in the sun
This study helps people who've had melanoma learn healthy habits around sun exposure and outdoor activity. You'll use a smartphone app, wear special tracking devices, and share information about your time outside to help researchers develop better ways to protect skin cancer survivors.
Chicago, IllinoisAges 18 years+ - NCT07530887RecruitingPhase 3
Melanoma Re-excision Study: Testing Observation Without Surgery
This study tests whether patients with moderate-thickness skin melanoma need additional surgery after their initial tumor removal, or if careful monitoring alone is enough. The goal is to avoid unnecessary surgery while keeping patients safe.
's-HertogenboschAges Any age - NCT07524114Recruiting
Blood test to find leftover cancer after treatment
This study uses a blood test to look for tiny bits of cancer DNA after you finish treatment. It may help doctors know if cancer is still there and guide next steps.
Toronto, OntarioAges 18 years+ - NCT07469709Recruiting
Cancer risk study using genetics and monitoring
This study looks at genetic and other factors in people with certain cancers to better understand personal cancer risks and improve monitoring. It may help find ways to detect changes earlier.
Candiolo, TurinAges 18 years+ - NCT07448831RecruitingPhase 2
Pembrolizumab before surgery for high-risk melanoma
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can help people with high-risk melanoma. It is for patients whose melanoma has not spread and who have not had prior treatment for melanoma.
Jette, Brussels CapitalAges 18 years+ - NCT03740503Recruiting
Study genes in people who respond unusually to treatment
This study looks at stored tumor samples to understand why some people respond much better or much worse than expected. The goal is to learn what the tumor’s genes might be telling doctors about response to treatment.
Toronto, OntarioAges 18 years+ - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+ - NCT07422779Recruiting
Immunotherapy for advanced melanoma study
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
LjubljanaAges 18 years+
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Melanoma (Skin Cancer) trials by city
Studies with a site in or near these metro areas.
Melanoma (Skin Cancer) trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for melanoma (skin cancer)?
- Yes. Clin2 currently lists 153 recruiting melanoma (skin cancer) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a melanoma (skin cancer) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a melanoma (skin cancer) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.